Anticoagulants Market Insights 2018-2025: Sanofi, Bristol-Myers Squibb, Bayer, Johnson & Johnson, Aspen

The global anticoagulants market was valued at $24,265 million in 2017, and is expected to reach $43,427 million by 2025, growing at a CAGR of 7.5% from 2018 to 2025.

The key players profiled in this report of anticoagulants market include Aspen Holdings, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, GlaxoSmithKline plc., Johnson & Johnson (Janssen Pharmaceuticals, Inc.), Pfizer, Inc., Portola Pharmaceuticals, Inc., and Sanofi S.A.

Anticoagulants Market Segmentation

The global anticoagulants market is segmented based on drug class, route of administration, application, and region. On the basis of drug class, the anticoagulants market is classified as NOACs, heparin and LMWH, vitamin K antagonist, and others. By route of administration, the market is segmented as oral anticoagulant and injectable anticoagulant. The various application markets are atrial fibrillation & heart attack, stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), and others. Region-wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Get Sample PDF Brochure : https://www.alliedmarketresearch.com/request-sample/1673

Anticoagulant drugs (also known as blood thinners) are chemical substances that prevent or reduce coagulation of blood and prolong the blood clotting time. These drugs are majorly used for high risk of blood clots in various medical conditions, such as atrial fibrillation, deep vein thrombosis, myocardial infarction, pulmonary embolism, stroke, and others. The global anticoagulants industry is anticipated to show significant growth during the forecast period, owing to increasing prevalence of venous thromboembolism (VTE) and cardiovascular disorders, growing adoption of novel oral anticoagulants (NOACs), and rising awareness of NOACs in the developing region. Furthermore, increase in number of obese and elderly people, higher unmet needs, and surge in demand of novel therapeutics further support the market growth. However, higher price of NOACs and lack of antidots for NOACs impede the market growth.

Segment Review

Presently, the NOACs segment is a major revenue-generating segment in the anticoagulants market and is anticipated to show dominance during the forecast period, owing to growing adoption of NOACs in developing countries and rising use of NOACs over the warfarin. Presently, NOACs drugs, such as rivaroxaban, betrixaban, apixaban, edoxaban, and dabigatran, are available in the market. Furthermore, NOACs offer various advantages over the warfarin, such as rapid onset action, lesser interaction with drugs and food, predictable pharmacokinetic action, shorter half-life, and no dietary restriction. These have been further supporting the market growth. On the other side, lack of antidote for NOACs and higher price impede the anticoagulants industry growth.

Presently, the atrial fibrillation & heart attack segment is a major revenue contributor and is anticipated to show dominance throughout the forecast period, owing to large target population and increased use of anticoagulants in treatment of these conditions. However, DVT is expected to witness fastest market growth, owing to increased prevalence of DVT and technological advancement in diagnosis of DVT.

Snapshot of the Asia-Pacific Anticoagulants Market

The Asia-Pacific region represents lucrative opportunities for players operating in the anticoagulants market, attributable to its increasing population base, rising prevalence of cardiovascular disease and VTE, developing economies, improving diagnosis rate, and growing demand for ideal therapeutics. Furthermore, continuous economic development with developing healthcare infrastructure and improving healthcare awareness have been further supporting the market growth. However, treatment expenses for anticoagulant drugs are anticipated to hamper the market growth in Asia-Pacific.

Do Purchase Enquiry at : https://www.alliedmarketresearch.com/purchase-enquiry/1673

About us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David C
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

This release was published on openPR.